These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 28129530)

  • 1. Covariate-Adjusted Restricted Mean Survival Times and Curves.
    Eng KH; Seagle BL
    J Clin Oncol; 2017 Feb; 35(4):465-466. PubMed ID: 28129530
    [No Abstract]   [Full Text] [Related]  

  • 2. Estimating restricted mean treatment effects with stacked survival models.
    Wey A; Vock DM; Connett J; Rudser K
    Stat Med; 2016 Aug; 35(19):3319-32. PubMed ID: 26934835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of survival data with missing measurements of a time-dependent binary covariate.
    Halabi S; Wun CC; Davis BR
    J Biopharm Stat; 2003 May; 13(2):253-70. PubMed ID: 12729393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case study of the effect of covariate adjustment in a sequential survival clinical trial.
    Todd S; Sahdra M
    J Biopharm Stat; 2001 Nov; 11(4):297-311. PubMed ID: 12018781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating mortality reduction by comparing survival curves.
    Nordling MK
    J Fam Pract; 2004 Nov; 53(11):929-30. PubMed ID: 15527736
    [No Abstract]   [Full Text] [Related]  

  • 6. On proportional hazards assumption under the random effects models.
    Xu R; Gamst A
    Lifetime Data Anal; 2007 Sep; 13(3):317-32. PubMed ID: 17638076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Joint models for efficient estimation in proportional hazards regression models.
    Slasor P; Laird N
    Stat Med; 2003 Jul; 22(13):2137-48. PubMed ID: 12820279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjusted survival curves with inverse probability weights.
    Cole SR; Hernán MA
    Comput Methods Programs Biomed; 2004 Jul; 75(1):45-9. PubMed ID: 15158046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating covariate-adjusted log hazard ratios in randomized clinical trials using cox proportional hazards models and nonparametric randomization based analysis of covariance.
    Saville BR; Koch GG
    J Biopharm Stat; 2013 Mar; 23(2):477-90. PubMed ID: 23437952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Causal proportional hazards models and time-constant exposure in randomized clinical trials.
    Loeys T; Goetghebeur E; Vandebosch A
    Lifetime Data Anal; 2005 Dec; 11(4):435-49. PubMed ID: 16328570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of time to event outcomes in randomized controlled trials by generalized additive models.
    Argyropoulos C; Unruh ML
    PLoS One; 2015; 10(4):e0123784. PubMed ID: 25906075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point.
    Huang B; Kuan PF
    Pharm Stat; 2018 May; 17(3):202-213. PubMed ID: 29282880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity analysis for missing outcomes in time-to-event data with covariate adjustment.
    Zhao Y; Saville BR; Zhou H; Koch GG
    J Biopharm Stat; 2016; 26(2):269-79. PubMed ID: 25635808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The type I error and power of non-parametric logrank and Wilcoxon tests with adjustment for covariates--a simulation study.
    Jiang H; Symanowski J; Paul S; Qu Y; Zagar A; Hong S
    Stat Med; 2008 Dec; 27(28):5850-60. PubMed ID: 18759373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term survival with non-proportional hazards: results from the Dutch Gastric Cancer Trial.
    Putter H; Sasako M; Hartgrink HH; van de Velde CJ; van Houwelingen JC
    Stat Med; 2005 Sep; 24(18):2807-21. PubMed ID: 16134134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing time-by-covariate interactions in relative survival models using restrictive cubic spline functions.
    Bolard P; Quantin C; Abrahamowicz M; Esteve J; Giorgi R; Chadha-Boreham H; Binquet C; Faivre J
    J Cancer Epidemiol Prev; 2002; 7(3):113-22. PubMed ID: 12665210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trials in oncology: a fertile ground for controversy.
    Markman M
    Curr Oncol Rep; 2003 Sep; 5(5):347-8. PubMed ID: 12895382
    [No Abstract]   [Full Text] [Related]  

  • 18. Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis.
    Lueza B; Rotolo F; Bonastre J; Pignon JP; Michiels S
    BMC Med Res Methodol; 2016 Mar; 16():37. PubMed ID: 27025706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Authors' reply to comments on 'Sample size calculation for the proportional hazards cure model'.
    Wang S; Zhang J; Lu W
    Stat Med; 2015 Jul; 34(17):2578-80. PubMed ID: 26133747
    [No Abstract]   [Full Text] [Related]  

  • 20. Nonparametric analysis of covariance for hypothesis testing with logrank and Wilcoxon scores and survival-rate estimation in a randomized clinical trial.
    Tangen CM; Koch GG
    J Biopharm Stat; 1999 May; 9(2):307-38. PubMed ID: 10379696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.